CAMP4 Therapeutics Corp
NASDAQ:CAMP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Sinofortune Financial Holdings Ltd
HKEX:8123
|
HK |
|
Jiangsu Lihua Animal Husbandry Co Ltd
SZSE:300761
|
CN |
|
N
|
Newland Pharmaceutical Co Ltd
SZSE:301277
|
CN |
|
China Xlx Fertiliser Ltd
HKEX:1866
|
CN |
|
China Tungsten and Hightech Materials Co Ltd
SZSE:000657
|
CN |
CAMP4 Therapeutics Corp
Total Current Assets
CAMP4 Therapeutics Corp
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
CAMP4 Therapeutics Corp
NASDAQ:CAMP
|
Total Current Assets
$114m
|
CAGR 3-Years
11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Current Assets
$29.1B
|
CAGR 3-Years
1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
6%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Assets
$18.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Assets
$29.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Assets
$11.2B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
7%
|
CAGR 10-Years
23%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Current Assets
$18B
|
CAGR 3-Years
4%
|
CAGR 5-Years
13%
|
CAGR 10-Years
20%
|
|
CAMP4 Therapeutics Corp
Glance View
CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company is headquartered in Cambridge, Massachusetts and currently employs 53 full-time employees. The company went IPO on 2024-10-11. The company is leveraging its RAP Platform to advance a pipeline of programs initially focused on metabolic and central nervous system (CNS) disorders with validated disease biology and potential market opportunities due to the significant unmet need of affected patients. Its lead product candidate, CMP-CPS-001, has the potential to be the first disease-modifying therapy for the treatment of urea cycle disorders. CMP-CPS-001 is designed to improve urea cycle activity by amplifying expression of CPS1, a key enzyme that catalyzes the first step of the urea cycle, by binding to a CPS1-specific regRNA. Its CNS development program, CMP-SYNGAP, is focused on addressing the underlying cause of SYNGAP1-related disorders.
See Also
What is CAMP4 Therapeutics Corp's Total Current Assets?
Total Current Assets
114m
USD
Based on the financial report for Dec 31, 2025, CAMP4 Therapeutics Corp's Total Current Assets amounts to 114m USD.
What is CAMP4 Therapeutics Corp's Total Current Assets growth rate?
Total Current Assets CAGR 3Y
11%
Over the last year, the Total Current Assets growth was 73%. The average annual Total Current Assets growth rates for CAMP4 Therapeutics Corp have been 11% over the past three years .
